Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Citius Oncology, Inc. (CTOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CTOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 116.23M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 2551598 | Beta - | 52 Weeks Range 0.55 - 40.50 | Updated Date 02/26/2025 |
52 Weeks Range 0.55 - 40.50 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 116225599 | Price to Sales(TTM) - |
Enterprise Value 116225599 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2000000 | Shares Floating - |
Shares Outstanding 2000000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 4 | Target Price - | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Citius Oncology, Inc.
Company Overview
History and Background
Citius Oncology, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on oncology. Founded in 2011.
Core Business Areas
- Oncology: Developing novel therapies for cancer treatment.
- Critical Care: Focusing on innovative products for unmet medical needs in critical care settings.
Leadership and Structure
Leonard Mazur is the Chairman and CEO. The company has a standard corporate structure with departments focused on R&D, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Mino-Lok: An antibiotic lock solution for catheter-related bloodstream infections (CRBSIs). Mino-Lok is currently under FDA review. Competitors include Taurolidine lock solutions such as DefenCath, and standard antibiotic flushes.
- Halo-Lido: A topical formulation for the relief of hemorrhoids. Currently in Phase 2b clinical trials. Competitors are other topical hemorrhoid treatments such as Preparation H, and Anucort-HC.
Market Dynamics
Industry Overview
The oncology and critical care markets are large and growing, driven by an aging population, increased cancer incidence, and advancements in medical technology.
Positioning
Citius Oncology is positioned as a company focused on addressing unmet needs with novel therapies, particularly in areas like CRBSIs and supportive care for cancer patients. Competitive advantage is its late-stage pipeline.
Total Addressable Market (TAM)
The TAM for Mino-Lok is estimated at several hundred million dollars, addressing a significant unmet need. The TAM for Halo-Lido is also substantial, given the prevalence of hemorrhoids. Citius is positioned to capture a share of these markets upon successful product launches.
Upturn SWOT Analysis
Strengths
- Late-stage pipeline with potential for near-term product launches
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Dependence on regulatory approvals
- Limited commercial infrastructure
- History of operating losses
Opportunities
- Potential for strategic partnerships
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Regulatory delays or rejection
- Competition from established pharmaceutical companies
- Failure to secure adequate financing
Competitors and Market Share
Key Competitors
- BMRN
- RDHL
- ALKS
Competitive Landscape
Citius Oncology competes with both established pharmaceutical companies and smaller biotech firms in the oncology and critical care markets. Its success depends on the differentiation and clinical efficacy of its products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by R&D progress rather than revenue generation. Clinical trial advancements have driven stock price fluctuations.
Future Projections: Future growth is dependent on successful commercialization of Mino-Lok and Halo-Lido. Analyst estimates vary based on approval timelines and market penetration.
Recent Initiatives: Recent initiatives include advancing clinical trials for Mino-Lok and Halo-Lido, and preparing for potential commercial launches.
Summary
Citius Oncology is a clinical-stage biotech company with promising late-stage assets, especially Mino-Lok. Successfully navigating regulatory hurdles and securing funding are key for their growth. Current profitability is challenged by clinical trial costs, but successful product launches could create value. Investors must watch for trial outcomes and commercialization strategies.
Similar Companies
ALKS
Alkermes Plc
ALKS
Alkermes Plc
BMRN
Biomarin Pharmaceutical Inc
BMRN
Biomarin Pharmaceutical Inc
RDHL
Redhill Biopharma Ltd
RDHL
Redhill Biopharma Ltd
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Citius Oncology, Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2022-12-08 | Chairman, CEO & President Mr. Leonard L. Mazur | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website |
Full time employees - | Website | ||
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.